NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $94,313 | -98.0% | 23,116 | -93.6% | 0.00% | -100.0% |
| Q3 2022 | $4,747,000 | -72.0% | 362,900 | -72.5% | 0.02% | -73.2% |
| Q2 2022 | $16,931,000 | -65.4% | 1,320,662 | -58.9% | 0.07% | -63.4% |
| Q1 2022 | $48,966,000 | -16.2% | 3,210,871 | -2.6% | 0.19% | -16.7% |
| Q4 2021 | $58,406,000 | +92.6% | 3,297,898 | +128.5% | 0.23% | +75.2% |
| Q3 2021 | $30,332,000 | +78.0% | 1,442,994 | +67.0% | 0.13% | +72.7% |
| Q2 2021 | $17,042,000 | -73.0% | 864,200 | -60.3% | 0.08% | -73.9% |
| Q1 2021 | $63,227,000 | +18.5% | 2,175,000 | +23.5% | 0.30% | +13.5% |
| Q4 2020 | $53,354,000 | +108.0% | 1,761,157 | +9.3% | 0.26% | +98.5% |
| Q3 2020 | $25,645,000 | -14.7% | 1,611,850 | +5.8% | 0.13% | -33.2% |
| Q2 2020 | $30,076,000 | +144.8% | 1,523,585 | +52.9% | 0.20% | +96.0% |
| Q1 2020 | $12,284,000 | – | 996,295 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
| Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
| Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
| Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
| StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
| Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
| First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
| GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
| Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
| Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |